Sofinnova Partners has announced a EUR 7m investment as lead investor in a EUR 12.3m round of financing in DBV Technologies, a French biopharmaceutical company that specialises in the development of allergy therapies and diagnostic tests. Apax Partners France also participated, injecting EUR 5m alongside historical investors, Cap Décisif and Creagro, which collectively provided EUR 350, 000.
PayPoint will use the proceeds to focus on core UK markets
Round for the biotechnology company extends the CHF 2.5m August 2019 round led by Redalpine
UnternehmerTUM Fonds III has a target of €150m and will focus on series-A and early-stage rounds
Deal is HTGF's 11th exit during the coronavirus pandemic, and comes seven years after the VC first invested in the company